Deal notes
This is an ATM facility event. The capacity shown is not cash raised.
Transaction overview
01Nautilus Biotechnology, Inc. disclosed an at-the-market program event: facility established. Authorized capacity is $125.0M. This event does not record cash proceeds raised.
- Financing type
- ATM
- Announcement date
- —
- SEC disclosure date
- Sep 11, 2026
- Agreement date
- Sep 11, 2026
- Pricing date
- —
- Closing date
- —
- Filing date
- Sep 18, 2026
- Status
- Announced
- Market cap before SEC disclosure
- $125.6M
- Prior closing price
- $0.9896
- Raise as % of market cap
- —
Market data · FMP
- Historical market cap
- $125,567,024
- Market date
- Sep 10, 2026
- Closing price
- $0.9896
- Latest reported shares outstanding
- 127,255,223
- Latest reported float shares
- 55,986,033
- Share-data date
- Sep 29, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.
Financial Modeling Prep ↗Financing terms
02At-the-market program
- Capital event
- Facility established
- Authorized capacity
- $125.0M
- Proceeds raised
- Not reported as raised
- Shares sold
- —
- Average sale price
- —
- Relevant period
- Not applicable
- Sales commission
- —
Fees & transaction economics
03- Placement agent / underwriting fee
- —
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
compensation payable to TD Cowen as sales agent equals up to 3.0% of the gross sales price
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
2026-09-11
C 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2026 NAUTILUS BIOTECHNOLOGY, INC. By: /s/ Sujal Patel Name: Sujal Patel Title: Chief Executive OfficerOriginal source ↗
sec_disclosure
C 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2026 NAUTILUS BIOTECHNOLOGY, INC. By: /s/ Sujal Patel Name: Sujal Patel Title: Chief Executive OfficerOriginal source ↗
compensation payable to TD Cowen as sales agent equals up to 3.0% of the gross sales price
compensation payable to TD Cowen as sales agent equals up to 3.0% of the gross sales priceOriginal source ↗
FMP reported market cap; as of 2026-09-10.
{"provider": "FMP", "symbol": "NAUT", "date": "2026-09-10", "marketCap": 125567024}Original source ↗